Heart failure is associated with a significant change in the energy metabolism of the heart. We aimed to elucidate the altered energetics during the progression of heart failure. We used radioactive metabolic tracers to assess the substrate uptake. In a rat model of heart failure, the glucose uptake increased significantly at the stage of left ventricular hypertrophy, whereas the uptake of fatty acids decreased at the stage of heart failure, with decreased energy reserve during the transition of cardiac hypertrophy to failure. Metabolic modulator which enhances glucose oxidation ameliorated the decrease in cardiac function. We also validated the close correlation with mitochondrial membrane potentials and 99mtechnetium sestamibi (99mTc-MIBI) in vivo and at the organ level. The retention of 99mTc-MIBI signals was correlated with the severity of heart failure. Nuclear medicine is a powerful tool to understand the mechanism of cardiac remodeling in heart failure.
{"title":"Analysis of Cardiac Metabolic Remodeling in Heart Failure Using Nuclear Medicine and Its Application: Japanese Society of Nuclear Cardiology Award.","authors":"Takao Kato","doi":"10.17996/anc.20-00112","DOIUrl":"https://doi.org/10.17996/anc.20-00112","url":null,"abstract":"<p><p>Heart failure is associated with a significant change in the energy metabolism of the heart. We aimed to elucidate the altered energetics during the progression of heart failure. We used radioactive metabolic tracers to assess the substrate uptake. In a rat model of heart failure, the glucose uptake increased significantly at the stage of left ventricular hypertrophy, whereas the uptake of fatty acids decreased at the stage of heart failure, with decreased energy reserve during the transition of cardiac hypertrophy to failure. Metabolic modulator which enhances glucose oxidation ameliorated the decrease in cardiac function. We also validated the close correlation with mitochondrial membrane potentials and <sup>99m</sup>technetium sestamibi (<sup>99m</sup>Tc-MIBI) in vivo and at the organ level. The retention of <sup>99m</sup>Tc-MIBI signals was correlated with the severity of heart failure. Nuclear medicine is a powerful tool to understand the mechanism of cardiac remodeling in heart failure.</p>","PeriodicalId":72228,"journal":{"name":"Annals of nuclear cardiology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133929/pdf/anc-6-91.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9393123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Noninvasive quantification of myocardial blood flow with PET is a vital tool for detecting and monitoring of coronary artery disease. However, current standard cylindrical PET scanners are not optimized for cardiac imaging because they are designed mainly for whole-body imaging. In this study, we proposed two compact geometries, the elliptical geometry and the D-shape geometry, for cardiac-dedicated PET systems. We then evaluated their performance compared with a whole-body-size cylindrical geometry by using the Geant4 Monte Carlo simulation toolkit. In the simulation, an elliptical water phantom was scanned for 10-sec, and we calculated the sensitivity and the noise-equivalent count rate (NECR). Subsequently, a digital chest phantom was scanned for 30-sec and the coincidence data were reconstructed by in-house image reconstruction software. We evaluated the image noise in the liver region and the contrast recoveries in the heart region. Even with the limited number of detectors, the proposed compact geometries showed higher sensitivity than the whole-body geometry. The D-shape geometry achieved 47% higher NECR and 44% lower image noise compared with the whole-body cylindrical geometry. However, the contrasts in the hot area obtained by the proposed compact geometries were not as good as that obtained by the whole-body cylindrical geometry. There was no considerable difference in image quality between the elliptical geometry and the D-shape geometry. In conclusion, the compact geometries we have proposed are promising designs for a high-sensitivity and low-cost cardiac-dedicated PET system. A further study using a defect phantom model is required to evaluate the contrast of cold areas.
{"title":"Simulation Study of High-sensitivity Cardiac-dedicated PET Systems with Different Geometries.","authors":"Go Akamatsu, Hideaki Tashima, Yuma Iwao, Miwako Takahashi, Eiji Yoshida, Taiga Yamaya","doi":"10.17996/anc.20-00114","DOIUrl":"https://doi.org/10.17996/anc.20-00114","url":null,"abstract":"<p><p>Noninvasive quantification of myocardial blood flow with PET is a vital tool for detecting and monitoring of coronary artery disease. However, current standard cylindrical PET scanners are not optimized for cardiac imaging because they are designed mainly for whole-body imaging. In this study, we proposed two compact geometries, the elliptical geometry and the D-shape geometry, for cardiac-dedicated PET systems. We then evaluated their performance compared with a whole-body-size cylindrical geometry by using the Geant4 Monte Carlo simulation toolkit. In the simulation, an elliptical water phantom was scanned for 10-sec, and we calculated the sensitivity and the noise-equivalent count rate (NECR). Subsequently, a digital chest phantom was scanned for 30-sec and the coincidence data were reconstructed by in-house image reconstruction software. We evaluated the image noise in the liver region and the contrast recoveries in the heart region. Even with the limited number of detectors, the proposed compact geometries showed higher sensitivity than the whole-body geometry. The D-shape geometry achieved 47% higher NECR and 44% lower image noise compared with the whole-body cylindrical geometry. However, the contrasts in the hot area obtained by the proposed compact geometries were not as good as that obtained by the whole-body cylindrical geometry. There was no considerable difference in image quality between the elliptical geometry and the D-shape geometry. In conclusion, the compact geometries we have proposed are promising designs for a high-sensitivity and low-cost cardiac-dedicated PET system. A further study using a defect phantom model is required to evaluate the contrast of cold areas.</p>","PeriodicalId":72228,"journal":{"name":"Annals of nuclear cardiology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133923/pdf/anc-6-95.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9398081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Sample size estimation is an important and integral part of a research protocol. While "how large a sample?" is a simple question, the answer is only meaningful within the context of the research question. Methods: Clear definitions of the variable of interest and target population parameters are key to estimating sample size. In turn the sample must be sized such that it can accurately detect the 'effect' of interest, adequately represent the target population and maintain maximum design efficiency. Four basic pieces of information are utilized in most sample estimation across all clinical research: significance level, power, magnitude of effect and variability of the variable of interest. Results/Discussion: Preliminary determination of these will greatly facilitate work with a biostatistician or a computer application to create a sample size estimation. While applications can support relatively simple sample size calculations consultation with a biostatistician is recommended.
{"title":"Sample Size Considerations: Basics for Preparing Clinical or Basic Research.","authors":"David N Williams, Kathryn A Williams","doi":"10.17996/anc.20-00122","DOIUrl":"https://doi.org/10.17996/anc.20-00122","url":null,"abstract":"<p><p><i>Background</i>: Sample size estimation is an important and integral part of a research protocol. While \"how large a sample?\" is a simple question, the answer is only meaningful within the context of the research question. <i>Methods</i>: Clear definitions of the variable of interest and target population parameters are key to estimating sample size. In turn the sample must be sized such that it can accurately detect the 'effect' of interest, adequately represent the target population and maintain maximum design efficiency. Four basic pieces of information are utilized in most sample estimation across all clinical research: significance level, power, magnitude of effect and variability of the variable of interest. <i>Results/Discussion</i>: Preliminary determination of these will greatly facilitate work with a biostatistician or a computer application to create a sample size estimation. While applications can support relatively simple sample size calculations consultation with a biostatistician is recommended.</p>","PeriodicalId":72228,"journal":{"name":"Annals of nuclear cardiology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133938/pdf/anc-6-81.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9398080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: The bone scan plays an important role for detecting number of conditions relating to bones, including: bone cancer or bone metastasis, bone inflammation. Extraosseous uptake, in particular, myocardial uptake, was observed in some patients examined with the bone scans. Positive uptake of 99mTc-labeled bone radiotracers is associated with cardiac amyloidosis. However, the frequency and cause of positive cardiac 99mTc-MDP uptake have not been fully studied. In this regard, the aim of this study was to assess the frequency and characteristics of patients with high myocardi-al uptake of bone scintigraphy in daily clinical practice setting. Methods: We retrospectively analyzed 4180 bone scintigraphies performed in daily clinical practice during 7-years period. The intensity of the myocardial uptake was graded based on a visual scale ranging from 0 to 3 points. Score 0 indicates the absence of uptake. Score 1 defined uptake less than that of bone (referred to as the adjacent rib). Uptake similar to that of bone was classified score 2. Score 3 was defined as uptake greater than that of reference bone. Positive myocardial uptake included a visual score 2 or 3. Result: Positive 99mTc-MDP myocardial uptake occurred in 12 patients among 4180 patients (0.3%). 7 of 12 positive scan patients were consistent with amyloidosis confirmed by biopsy. In these patients, the mean age was 75.6 ± 5.2 years old. Ten cases showed biventricular uptake and 2 showed LV uptake only. Conclusion: Positive cardiac uptake of bone scintigraphic agents was present in 0.3% of bone scintigraphies in a clinical practice setting. This may be a sign of cardiac amyloidosis involvement which may give the presence of extraosseous bone tracer uptake its own importance and a new role.
{"title":"Positive Myocardial Uptake of Bone Scintigraphic Agents Associated with Cardiac Amyloidosis: Frequency of Positive Uptake Data Based on Daily Clinical Practice.","authors":"Shigeru Fukuzawa, Shinichi Okino, Hikaru Ishiwaki, Yo Iwata, Takashi Uchiyama, Nobuyuki Kuroiwa, Norikiyo Oka, Noeru Shibayama, Masayuki Inagaki","doi":"10.17996/anc.20-00121","DOIUrl":"https://doi.org/10.17996/anc.20-00121","url":null,"abstract":"<p><p><i>Objective</i>: The bone scan plays an important role for detecting number of conditions relating to bones, including: bone cancer or bone metastasis, bone inflammation. Extraosseous uptake, in particular, myocardial uptake, was observed in some patients examined with the bone scans. Positive uptake of <sup>99m</sup>Tc-labeled bone radiotracers is associated with cardiac amyloidosis. However, the frequency and cause of positive cardiac <sup>99m</sup>Tc-MDP uptake have not been fully studied. In this regard, the aim of this study was to assess the frequency and characteristics of patients with high myocardi-al uptake of bone scintigraphy in daily clinical practice setting. <i>Methods</i>: We retrospectively analyzed 4180 bone scintigraphies performed in daily clinical practice during 7-years period. The intensity of the myocardial uptake was graded based on a visual scale ranging from 0 to 3 points. Score 0 indicates the absence of uptake. Score 1 defined uptake less than that of bone (referred to as the adjacent rib). Uptake similar to that of bone was classified score 2. Score 3 was defined as uptake greater than that of reference bone. Positive myocardial uptake included a visual score 2 or 3. <i>Result</i>: Positive <sup>99m</sup>Tc-MDP myocardial uptake occurred in 12 patients among 4180 patients (0.3%). 7 of 12 positive scan patients were consistent with amyloidosis confirmed by biopsy. In these patients, the mean age was 75.6 ± 5.2 years old. Ten cases showed biventricular uptake and 2 showed LV uptake only. <i>Conclusion</i>: Positive cardiac uptake of bone scintigraphic agents was present in 0.3% of bone scintigraphies in a clinical practice setting. This may be a sign of cardiac amyloidosis involvement which may give the presence of extraosseous bone tracer uptake its own importance and a new role.</p>","PeriodicalId":72228,"journal":{"name":"Annals of nuclear cardiology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133927/pdf/anc-6-27.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9398083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01Epub Date: 2020-08-31DOI: 10.17996/anc.20-00123
David H Birnie, Niko Tzemos, Pablo B Nery
Introduction: The Japanese Circulation Society (JCS) recently published new guidelines for the diagnosis and treatment of Cardiac Sarcoidosis (CS). There are two other guideline documents, the World Association of Sarcoidosis and Other Granulomatous Disorders Sarcoidosis Organ (WASOG) Assessment Instrument created in 1999 and updated in 2014. Also, in 2014, the Heart Rhythm Society (HRS) published their international guideline document. As co-chair of the HRS document I have been invited to compare and contrast the management aspects of the HRS guidelines with the new JCS document. Comments: (i) The HRS document recommended a stepwise approach to VT management and the JCS document is somewhat similar; but with some key differences. (ii) The HRS statement suggested that an ICD for CS patients with an indication for a pacemaker "can be useful". The JCS document take a similar position although with some additional criteria related to National Health Institute Coverage guidelines. (iii) Both HRS and the JCS documents agree that ICDs are recommended in patients with general guideline indications for primary prevention (i.e. LVEF less than 35%). However which additional patients should be considered for ICDs is controversial. The 2016 JCS document is broadly similar, with the major exception that it is recommended that all patients with LVEF 35-50% should have an EP study. Conclusion: The Japanese have been leaders in many aspects of CS including in guideline development. It is clear that the future of CS management is bright, with increasing international collaborations and also multiple efforts underway to obtain higher quality data to inform future guidelines.
{"title":"Comparing and Contrasting Guidelines for the Management of Cardiac Sarcoidosis.","authors":"David H Birnie, Niko Tzemos, Pablo B Nery","doi":"10.17996/anc.20-00123","DOIUrl":"10.17996/anc.20-00123","url":null,"abstract":"<p><p><i>Introduction</i>: The Japanese Circulation Society (JCS) recently published new guidelines for the diagnosis and treatment of Cardiac Sarcoidosis (CS). There are two other guideline documents, the World Association of Sarcoidosis and Other Granulomatous Disorders Sarcoidosis Organ (WASOG) Assessment Instrument created in 1999 and updated in 2014. Also, in 2014, the Heart Rhythm Society (HRS) published their international guideline document. As co-chair of the HRS document I have been invited to compare and contrast the management aspects of the HRS guidelines with the new JCS document. <i>Comments</i>: (i) The HRS document recommended a stepwise approach to VT management and the JCS document is somewhat similar; but with some key differences. (ii) The HRS statement suggested that an ICD for CS patients with an indication for a pacemaker \"can be useful\". The JCS document take a similar position although with some additional criteria related to National Health Institute Coverage guidelines. (iii) Both HRS and the JCS documents agree that ICDs are recommended in patients with general guideline indications for primary prevention (i.e. LVEF less than 35%). However which additional patients should be considered for ICDs is controversial. The 2016 JCS document is broadly similar, with the major exception that it is recommended that all patients with LVEF 35-50% should have an EP study. <i>Conclusion</i>: The Japanese have been leaders in many aspects of CS including in guideline development. It is clear that the future of CS management is bright, with increasing international collaborations and also multiple efforts underway to obtain higher quality data to inform future guidelines.</p>","PeriodicalId":72228,"journal":{"name":"Annals of nuclear cardiology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133928/pdf/anc-6-61.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9449497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01Epub Date: 2020-08-31DOI: 10.17996/anc.20-00133
Andrew Van Tosh, Kenneth J Nichols
The COVID-19 pandemic has altered all aspects of performing medical procedures throughout the world. It is important to stratify patients into categories according to the likelihood that a requested exam will result in a change in acute management. Health care staff should maintain adequate distancing and engage in frequent hand washing, and personnel who are patient-facing should put on PPE at all times. All patient-touching apparatus should be disinfected between patients according to the Infection Control protocols of the institutions. Most labs have chosen to have patients wear surgical masks to afford some level of protection for them. Efforts should be implemented to enable remote reading and remote reporting of study results. The guidelines presented in this paper are based on the currently available information regarding SARS-CoV-2 (COVID-19) viral infections, but it is essential that all laboratories comply with evolving recommendations of their institutions and public health authorities.
{"title":"Approach to Protecting Patients and Staff in Nuclear Cardiology Laboratories in Response to the COVID-19 Pandemic.","authors":"Andrew Van Tosh, Kenneth J Nichols","doi":"10.17996/anc.20-00133","DOIUrl":"10.17996/anc.20-00133","url":null,"abstract":"<p><p>The COVID-19 pandemic has altered all aspects of performing medical procedures throughout the world. It is important to stratify patients into categories according to the likelihood that a requested exam will result in a change in acute management. Health care staff should maintain adequate distancing and engage in frequent hand washing, and personnel who are patient-facing should put on PPE at all times. All patient-touching apparatus should be disinfected between patients according to the Infection Control protocols of the institutions. Most labs have chosen to have patients wear surgical masks to afford some level of protection for them. Efforts should be implemented to enable remote reading and remote reporting of study results. The guidelines presented in this paper are based on the currently available information regarding SARS-CoV-2 (COVID-19) viral infections, but it is essential that all laboratories comply with evolving recommendations of their institutions and public health authorities.</p>","PeriodicalId":72228,"journal":{"name":"Annals of nuclear cardiology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133924/pdf/anc-6-11.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9393126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Obesity increases the risk for development of heart failure (HF) but, when present is likely to be related to better outcomes in patients with HF. This study aimed to clarify the paradoxical prognostic values of visceral obesity in association with cardiac sympathetic function in HF patients. Methods and Results: A total of 653 consecutive patients with systolic HF who underwent visceral adiposity area (VAA) measurements using a computed tomographic technique were divided into 3 groups: VAA 1, area <80 cm2; VAA 2, area 80-140 cm2; VAA 3, area >140 cm2. Sympathetic innervation was quantified by 123I-MIBG cardiac activity. Patients were followed up for an average of 22 months with a primary endpoint of lethal cardiac events (CE). The CE group (n=200) had a lower late heart-to mediastinum ratio (HMR) and a smaller VAA than those in the non-CE group. Rates of overall CE/HF death were inversely correlated with VAA: 39.2% ± 6.2% for VAA 1, 27.4% ± 19.9% for VAA 2 and 24.1% ± 15.3% for VAA 3. In addition to sudden cardiac death rate, lethal arrhythmic event rate increased in association with visceral fat obesity: 3.0% for VAA 1, 7.5% for VAA 2 and 8.8% for VAA 3. Late HMR identified high-risk sub-populations in each group. Conclusion: Visceral obesity has paradoxical prognostic implications in terms of HF mortality and lethal arrhythmic/sudden cardiac death events. Cardiac sympathetic denervation and quantitative visceral adiposity are synergistically associated with overall cardiac mortality, contributing to better risk stratification of HF patients.
{"title":"Paradoxical Prognostic Implications of Visceral Adiposity for Lethal Cardiac Events in Association with Impaired Cardiac Sympathetic Innervation in Chronic Heart Failure.","authors":"Takahiro Doi, Tomoaki Nakata, Takahiro Noto, Tomohiro Mita, Satoshi Yuda, Akiyoshi Hashimoto","doi":"10.17996/anc.20-00118","DOIUrl":"https://doi.org/10.17996/anc.20-00118","url":null,"abstract":"<p><p><i>Background</i>: Obesity increases the risk for development of heart failure (HF) but, when present is likely to be related to better outcomes in patients with HF. This study aimed to clarify the paradoxical prognostic values of visceral obesity in association with cardiac sympathetic function in HF patients. <i>Methods and Results</i>: A total of 653 consecutive patients with systolic HF who underwent visceral adiposity area (VAA) measurements using a computed tomographic technique were divided into 3 groups: VAA 1, area <80 cm<sup>2</sup>; VAA 2, area 80-140 cm<sup>2</sup>; VAA 3, area >140 cm<sup>2</sup>. Sympathetic innervation was quantified by <sup>123</sup>I-MIBG cardiac activity. Patients were followed up for an average of 22 months with a primary endpoint of lethal cardiac events (CE). The CE group (n=200) had a lower late heart-to mediastinum ratio (HMR) and a smaller VAA than those in the non-CE group. Rates of overall CE/HF death were inversely correlated with VAA: 39.2% ± 6.2% for VAA 1, 27.4% ± 19.9% for VAA 2 and 24.1% ± 15.3% for VAA 3. In addition to sudden cardiac death rate, lethal arrhythmic event rate increased in association with visceral fat obesity: 3.0% for VAA 1, 7.5% for VAA 2 and 8.8% for VAA 3. Late HMR identified high-risk sub-populations in each group. <i>Conclusion</i>: Visceral obesity has paradoxical prognostic implications in terms of HF mortality and lethal arrhythmic/sudden cardiac death events. Cardiac sympathetic denervation and quantitative visceral adiposity are synergistically associated with overall cardiac mortality, contributing to better risk stratification of HF patients.</p>","PeriodicalId":72228,"journal":{"name":"Annals of nuclear cardiology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133937/pdf/anc-6-15.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9393122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A pproximately six years ago, the Japanese Society of Nuclear Cardiology (JSNC) launched its official journal, the Annals of Nuclear Cardiology (ANC), with the ultimate goal of advancing research and clinical practice by those in the field of nuclear cardiology, including physicians, technologists, and scientists, as well as the industries that support them. Initially JSNC aimed to promote its own members’ research and clinical practice and therefore it required any non-JSNC members who wanted to submit their manuscript to ANC to become JSNC members. However, as ANC has become bettter known among physicians and researchers on different continents and as the nature of research itself has moved further towards examining issues on a global scale, the time has come to open ANC not only to our members but to all nuclear cardiology researchers around the world. Beginning this year, ANC therefore no longer requires authors to become JSNC members or to pay a submission fee. With this change, ANC is now more accessible to everyone in the nuclear cardiology field around the world. In this spirit, the editorial board of ANC is working to ensure that articles published in ANC can be accessed via major search engines. Board members have been working very hard to collect the information necessary to apply to such search engines, but further steps are necessary. First, ANC needs to have a more international perspective. Therefore, the ANC editorial board is looking to include international advisory members among its ranks. This move will be coming soon. We are planning to apply to PubMed or PubMed Central operated by the National Institute of Health in the United States. Improving the quality of original articles and technical articles is now even more important and so last year we started an editorial support program. Through this program, editorial board members work with authors preparing manuscripts for submission. Beginning with this edition of ANC, original articles accepted for publication will have undergone thorough scientific editing as part of ANC’s process to support authors in manuscript preparation and to improve the overall quality of manuscripts. Authors sometimes overlook the new insight their studies may provide. In this regard, editorial board members, who have great depth of experience, will endeavour to help these authors to identify such new insights from their work. For this issue of ANC at least, the number of original articles is still limited. However, I expect this number to grow in the coming years. Along with increasing the quantity of manuscripts, we continuously aim to improve their quality. In this regard, the review process is very important. Therefore, I have asked experienced reviewers in Asia, the UK, Europe, North America, and South America to review articles submitted to ANC. Among ANC reviewers this year are a number of core American Society of Nuclear Cardiology members. I am especially grateful to those who have been wil
{"title":"ANC Opens up to the World","authors":"K. Yoshinaga","doi":"10.17996/anc.20-00001","DOIUrl":"https://doi.org/10.17996/anc.20-00001","url":null,"abstract":"A pproximately six years ago, the Japanese Society of Nuclear Cardiology (JSNC) launched its official journal, the Annals of Nuclear Cardiology (ANC), with the ultimate goal of advancing research and clinical practice by those in the field of nuclear cardiology, including physicians, technologists, and scientists, as well as the industries that support them. Initially JSNC aimed to promote its own members’ research and clinical practice and therefore it required any non-JSNC members who wanted to submit their manuscript to ANC to become JSNC members. However, as ANC has become bettter known among physicians and researchers on different continents and as the nature of research itself has moved further towards examining issues on a global scale, the time has come to open ANC not only to our members but to all nuclear cardiology researchers around the world. Beginning this year, ANC therefore no longer requires authors to become JSNC members or to pay a submission fee. With this change, ANC is now more accessible to everyone in the nuclear cardiology field around the world. In this spirit, the editorial board of ANC is working to ensure that articles published in ANC can be accessed via major search engines. Board members have been working very hard to collect the information necessary to apply to such search engines, but further steps are necessary. First, ANC needs to have a more international perspective. Therefore, the ANC editorial board is looking to include international advisory members among its ranks. This move will be coming soon. We are planning to apply to PubMed or PubMed Central operated by the National Institute of Health in the United States. Improving the quality of original articles and technical articles is now even more important and so last year we started an editorial support program. Through this program, editorial board members work with authors preparing manuscripts for submission. Beginning with this edition of ANC, original articles accepted for publication will have undergone thorough scientific editing as part of ANC’s process to support authors in manuscript preparation and to improve the overall quality of manuscripts. Authors sometimes overlook the new insight their studies may provide. In this regard, editorial board members, who have great depth of experience, will endeavour to help these authors to identify such new insights from their work. For this issue of ANC at least, the number of original articles is still limited. However, I expect this number to grow in the coming years. Along with increasing the quantity of manuscripts, we continuously aim to improve their quality. In this regard, the review process is very important. Therefore, I have asked experienced reviewers in Asia, the UK, Europe, North America, and South America to review articles submitted to ANC. Among ANC reviewers this year are a number of core American Society of Nuclear Cardiology members. I am especially grateful to those who have been wil","PeriodicalId":72228,"journal":{"name":"Annals of nuclear cardiology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73166847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Triglyceride deposit cardiomyovasculopathy (TGCV) is a newly identified disease that was discovered in individuals who required cardiac transplantation in Japan in 2008. Defective intracellular lipolysis causes triglyceride (TG) accumulation in the myocardium and coronary artery vascular smooth muscle cells, which results in severe heart failure and coronary artery disease with poor prognosis. A known cause of TGCV is a genetic deficiency of adipose triglyceride lipase (ATGL), a rate-limiting enzyme in the intracellular hydrolysis of TG. TGCV is classified into primary TGCV with ATGL mutations and idiopathic TGCV without ATGL mutations. Since its discovery, the Japan TGCV Study Group has attempted to elucidate its pathophysiology, develop diagnostic procedures, and specific treatment. Myocardial scintigraphy with iodine-123-β-methyl iodophenyl-pentadecanoic acid (123I-BMIPP) is a unique imaging modality for evaluating myocardial lipolysis in vivo. The washout rate of 123I-BMIPP is an essential indicator for the diagnosis of TGCV. Along with our efforts to provide awareness of and insights into this disease concept, we found that the cumulative number of clinically diagnosed patients has reached >200 and the cases are distributed throughout Japan. In addition, we successfully completed three investigator-initiated clinical trials of a potential therapeutic agent (CNT-01) for TGCV, which was assigned by the Ministry of Health, Labour, and Welfare, Japan, under the SAKIGAKE Designation System in June 2020. Here, we provide the Diagnostic Criteria 2020 for TGCV in order to further promote this "rare and intractable disease" project.
{"title":"The Diagnostic Criteria 2020 for Triglyceride Deposit Cardiomyovasculopathy.","authors":"Kunihisa Kobayashi, Yasuhiko Sakata, Hideyuki Miyauchi, Yoshihiko Ikeda, Yasuyuki Nagasawa, Kenichi Nakajima, Kazunori Shimada, Junji Kozawa, Hiroyuki Hao, Tetsuya Amano, Hiroshi Yoshida, Tohru Inaba, Chikako Hashimoto, Ken-Ichi Hirano","doi":"10.17996/anc.20-00131","DOIUrl":"10.17996/anc.20-00131","url":null,"abstract":"<p><p>Triglyceride deposit cardiomyovasculopathy (TGCV) is a newly identified disease that was discovered in individuals who required cardiac transplantation in Japan in 2008. Defective intracellular lipolysis causes triglyceride (TG) accumulation in the myocardium and coronary artery vascular smooth muscle cells, which results in severe heart failure and coronary artery disease with poor prognosis. A known cause of TGCV is a genetic deficiency of adipose triglyceride lipase (ATGL), a rate-limiting enzyme in the intracellular hydrolysis of TG. TGCV is classified into primary TGCV with ATGL mutations and idiopathic TGCV without ATGL mutations. Since its discovery, the Japan TGCV Study Group has attempted to elucidate its pathophysiology, develop diagnostic procedures, and specific treatment. Myocardial scintigraphy with iodine-123-<i>β</i>-methyl iodophenyl-pentadecanoic acid (<sup>123</sup>I-BMIPP) is a unique imaging modality for evaluating myocardial lipolysis <i>in vivo.</i> The washout rate of <sup>123</sup>I-BMIPP is an essential indicator for the diagnosis of TGCV. Along with our efforts to provide awareness of and insights into this disease concept, we found that the cumulative number of clinically diagnosed patients has reached >200 and the cases are distributed throughout Japan. In addition, we successfully completed three investigator-initiated clinical trials of a potential therapeutic agent (CNT-01) for TGCV, which was assigned by the Ministry of Health, Labour, and Welfare, Japan, under the SAKIGAKE Designation System in June 2020. Here, we provide the Diagnostic Criteria 2020 for TGCV in order to further promote this \"rare and intractable disease\" project.</p>","PeriodicalId":72228,"journal":{"name":"Annals of nuclear cardiology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133930/pdf/anc-6-99.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9393125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}